A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure

[1]  Jean S. Campbell,et al.  Liver regeneration. , 2012, Journal of hepatology.

[2]  C. Smith.  Diagnostic tests (1) – sensitivity and specificity , 2012, Phlebology.

[3]  D. Solís.  US Food and Drug Administration , 2010 .

[4]  E. Delwart,et al.  Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia , 2008, Hepatology.

[5]  France Mentré,et al.  The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects model , 2007, Statistics in medicine.

[6]  Harel Dahari,et al.  Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. , 2007, Journal of theoretical biology.

[7]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[8]  M O Karlsson,et al.  Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.

[9]  S. Mudan,et al.  LIVER REGENERATION: MECHANISMS, MYSTERIES AND MORE , 2007, ANZ journal of surgery.

[10]  E. Snoeck,et al.  Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. , 2006, British journal of clinical pharmacology.

[11]  France Mentré,et al.  Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..

[12]  J. Layden-Almer,et al.  Viral kinetics in the treatment of chronic hepatitis C , 2006, Journal of viral hepatitis.

[13]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[14]  D. Wodarz.  Mathematical models of immune effector responses to viral infections: Virus control versus the development of pathology , 2005 .

[15]  Eva Herrmann,et al.  New kinetic models for the hepatitis C virus , 2005, Hepatology.

[16]  L. Wahl,et al.  Perspectives on the basic reproductive ratio , 2005, Journal of The Royal Society Interface.

[17]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[18]  Richard Berg,et al.  Sensitivity and specificity. , 2005, Clinical medicine & research.

[19]  A. Perelson,et al.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection , 2004, Nature.

[20]  P. Marcellin,et al.  Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial , 2004, American Journal of Gastroenterology.

[21]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[22]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[23]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[24]  M. Brunetto,et al.  Sustained Response to Interferon–Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase , 2002, Antiviral therapy.

[25]  L. Price,et al.  LIVER REGENERATION AND SURGICAL OUTCOME IN DONORS OF RIGHT‐LOBE LIVER GRAFTS , 2003, Transplantation.

[26]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, Gastroenterology.

[27]  J. Hoofnagle,et al.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10‐12, 2002 , 2002, Hepatology.

[28]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[29]  T. Layden,et al.  Viral kinetics of hepatitis C: New insights and remaining limitations , 2002, Hepatology.

[30]  Alan S Perelson,et al.  HIV-1 infection and low steady state viral loads , 2002, Bulletin of mathematical biology.

[31]  S. Sherlock,et al.  Diseases of the Liver and Biliary System , 1955 .

[32]  S. Zeuzem,et al.  The kinetics of hepatitis C virus infection. , 2001, Clinics in liver disease.

[33]  William M. Lee,et al.  Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C , 2001 .

[34]  M. Shiffman,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.

[35]  J. Reichen,et al.  Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.

[36]  K. Gutekunst,et al.  Improved Version 2.0 Qualitative and Quantitative AMPLICOR Reverse Transcription-PCR Tests for Hepatitis C Virus RNA: Calibration to International Units, Enhanced Genotype Reactivity, and Performance Characteristics , 2000, Journal of Clinical Microbiology.

[37]  A S Perelson,et al.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. , 2000, The Journal of infectious diseases.

[38]  É. Moulines,et al.  Convergence of a stochastic approximation version of the EM algorithm , 1999 .

[39]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[40]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[41]  M. Cramp.  Diseases of the Liver and Biliary System: 10th edn , 1997 .

[42]  Eugene R. Schiff,et al.  National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C , 1997, Hepatology.

[43]  K. Reddy,et al.  Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy , 1996, Annals of Internal Medicine.

[44]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[45]  K. Reddy,et al.  Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. , 1996, Annals of internal medicine.

[46]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[47]  Hua-Lin Wu,et al.  Detection of HCV RNA in saliva, urine, seminal fluid, and ascites , 1992, Journal of medical virology.

[48]  D. Serrão.  Pathology of the Liver, 2nd Edn., R.N.M. MacSween, P.P. Anthony, P.J. Scheuer (Eds.). Churchill Livingstone, London (1987), ISBN: 0-443-03049-9 , 1987 .

[49]  Stephen E. Fienberg,et al.  Discrete Multivariate Analysis: Theory and Practice , 1976 .

[50]  Arindam Banerjee,et al.  Submitted for publication , 1981 .